Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Owlet (OWLT) Asset Writedowns and Impairment (2020 - 2026)

Owlet (OWLT) reported Asset Writedowns and Impairment of -$25000.0 for Q1 2026, down 139.06% year-over-year from $64000.0 in Q1 2025, and down 316.67% on a QoQ basis from -$6000.0 in Q4 2025.

Owlet (OWLT) has 6 years of Asset Writedowns and Impairment data on file, last reported at -$25000.0 in Q1 2026.

  • Quarterly Asset Writedowns and Impairment fell 139.06% year-over-year to -$25000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43000.0 (down 101.83% YoY) and the FY2025 annual result came in at $46000.0, down 97.58% from the prior year.
  • Asset Writedowns and Impairment slipped to -$25000.0 in Q1 2026 per OWLT's latest filing, from -$6000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $2.3 million in Q4 2024 and bottomed at -$221000.0 in Q3 2023.
  • The 4-year median for Asset Writedowns and Impairment is $9000.0 (2024), against an average of $180769.2.
  • The widest annual swing landed in 2024, when Asset Writedowns and Impairment surged 1060.31%; it then plunged 1200.0% in 2025.
  • Tracing OWLT's Asset Writedowns and Impairment over 4 years: stood at $194000.0 in 2023, then surged by 1060.31% to $2.3 million in 2024, then slumped by 100.27% to -$6000.0 in 2025, then sank by 316.67% to -$25000.0 in 2026.
  • Per Business Quant, the three latest OWLT Asset Writedowns and Impairment figures stand at -$25000.0 (Q1 2026), -$6000.0 (Q4 2025), and $32000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Owlet 150.10 Mn 109.09 Mn 12.24 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -25,000.00
Mar 31, 2026 -25,000.00
Dec 31, 2025 -6,000.00
Dec 31, 2025 -6,000.00
Sep 30, 2025 32,000.00
Sep 30, 2025 32,000.00
Jun 30, 2025 -44,000.00
Jun 30, 2025 -44,000.00
Mar 31, 2025 64,000.00
Mar 31, 2025 64,000.00
Dec 31, 2024 2.25 Mn
Dec 31, 2024 2.25 Mn
Sep 30, 2024 37,000.00
Sep 30, 2024 37,000.00
Jun 30, 2024 4,000.00
Jun 30, 2024 4,000.00
Mar 31, 2024 9,000.00
Mar 31, 2024 9,000.00
Dec 31, 2023 194,000.00
Dec 31, 2023 194,000.00
Sep 30, 2023 -221,000.00
Sep 30, 2023 -221,000.00
Jun 30, 2023 -28,000.00
Jun 30, 2023 -28,000.00
Mar 31, 2023 83,000.00
Mar 31, 2023 83,000.00
Dec 31, 2021 1.50 Mn
Dec 31, 2021 1.50 Mn
Dec 31, 2020 417,000.00
Dec 31, 2020 417,000.00